CClinicalTrials.gg
Status unknownNCT04519593Updated Jul 14, 2021

ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma

An interventional study of Laparoscopic myomectomy with prior temporary uterine blood supply occlusion and Conventional laparoscopic myomectomy in Uterine Leiomyoma, Uterine Fibroid and Leiomyoma, Uterine, sponsored by Mother and Child Clinic Saint-Petersburg. Status unknown at 1 site in Russian Federation. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-14.

Sponsored by Mother and Child Clinic Saint-Petersburg · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

A phase 3 multicenter unblinded randomized controlled trial comparing the temporary uterine blood supply occlusion with conventional approach during laparoscopic myomectomy in patients with uterine leiomyoma.

Read the detailed description

Primary endpoints

  • Assess the volume of blood loss

Secondary endpoints

  • Compare the rates of intra- and postoperative complications, the necessity of blood transfusion, length of surgery, length of hospital and ICU stay, and leiomyoma symptoms relief
  • Determine the procedure impact on fertility by evaluating the level of anti-mullerian hormone, pregnancy rates, pregnancy complications, and the way of delivery

Patients who meet study inclusion criteria will be randomized into one of two treatment arms: 1) laparoscopic myomectomy preceded by temporary uterine blood supply occlusion or 2) laparoscopic myomectomy with a conventional approach.

Sixty patients will undergo laparoscopic myomectomy preceded by temporary uterine blood supply occlusion performed by gynecologists at Mother and Child Clinic Saint-Petersburg and other institutions participating in the study. Sixty patients will undergo conventional laparoscopic myomectomy performed by gynecologists at Mother and Child Clinic Saint-Petersburg and other institutions participating in the study.

Patients eligible for inclusion, after signing an informed voluntary consent to participate in the study, will be randomized in a 1:1 ratio to the treatment groups using stratification by age, size, and leiomyoma nodes location.

02

Conditions studied

  • Uterine Leiomyoma
  • Uterine Fibroid
  • Leiomyoma, Uterine
  • Myoma;Uterus
  • Laparoscopic Myomectomy
  • Postoperative Complications
  • Blood Loss, Surgical
  • Fertility Issues
  • Pregnancy Complications

Keywords

  • temporary uterine artery occlusion
  • temporary uterine blood supply occlusion
03

In context

Leiomyoma

490 studies on the registry are indexed under Leiomyoma; 81 are open to participants now.

This study's planned enrollment of 120 is above the median of 62 across 345 interventional studies indexed under Leiomyoma.

Browse Leiomyoma studies →

Lead sponsor

This is the only study on the registry with Mother and Child Clinic Saint-Petersburg as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Symptomatic uterine leiomyoma
  • Size of leiomyoma node >5 cm based on imaging
  • Leiomyoma node types 3, 4, 5, 6 according to The International Federation of Gynecology and Obstetrics (FIGO) classification or type 2 not feasible to be removed during hysteroscopy
  • Single or multiple nodes
  • Absent contraindications for laparoscopic myomectomy
  • Voluntarily signed informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Asymptomatic uterine leiomyoma
  • Size of leiomyoma node \<5 cm based on imaging
  • Absence of leiomyoma node types 3, 4, 5, 6 according to FIGO classification and type 2 not feasible to be removed during hysteroscopy
  • Planned simultaneous hysteroscopy with leiomyoma node excision
  • Current pregnancy and breastfeeding
  • Suspicion of a malignant uterine tumor
  • Prior uterine leiomyoma surgery
  • Contraindications for laparoscopic myomectomy
  • Lack of decision-making capacity hindering signing the consent to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Laparoscopic myomectomy with temporary blood supply occlusion

    Laparoscopic myomectomy is performed with prior visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.

    Procedure: Laparoscopic myomectomy with prior temporary uterine blood supply occlusion

  • Active comparator
    Conventional laparoscopic myomectomy

    Laparoscopic myomectomy is performed without prior temporary blood supply occlusion.

    Procedure: Conventional laparoscopic myomectomy

Interventions

  • ProcedureLaparoscopic myomectomy with prior temporary uterine blood supply occlusion

    Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.

    Also known as: Temporary uterine arteries occlusion

  • ProcedureConventional laparoscopic myomectomy

    Laparoscopic myomectomy without prior temporary uterine blood supply occlusion

06

What researchers measure

Primary outcomes

  1. Blood loss

    Evaluation of blood loss volume

    Time frame: At the end of the intervention

Secondary outcomes

  1. Treatment characteristics

    Rates of intra- and postoperative complications, necessity of blood transfusion, length of surgery, length of hospital and ICU stay, leiomyoma symptoms relief

    Time frame: During 6 months since the intervention

  2. Impact on fertility

    Level of anti-mullerian hormone, rate of pregnancy, pregnancy complications, the way of delivery

    Time frame: During 18 months since the intervention

07

Study locations

1 of 1 sites recruiting
  • Mother and Child Clinic Saint-Petersburg
    Saint Petersburg, 199106, Russian Federation
    • Andrei Dubinin, MD, PhD · Contact · andub@mail.ru · +79811506112
    • Andrei Dubinin, MD, PhD · Principal investigator
    • Pavel Sorokin, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04519593
Lead sponsor
Mother and Child Clinic Saint-Petersburg
Responsible party
Andrey Dubinin, MD, PhD (Gynecologist, Mother and Child Clinic Saint-Petersburg) — Principal investigator
First posted
Aug 19, 2020
Start date
Sep 27, 2020
Primary completion
Aug 31, 2022 (estimated)
Completion
Nov 1, 2022 (estimated)
Last update
Jul 14, 2021

Study contacts

Andrei Dubinin, MD, PhD
Contact
andub@mail.ru
+79811506112
Pavel Sorokin, MD
Contact
sor-pavel@ya.ru
+79835218691

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion